Back to Search Start Over

Efficacy and tolerability of mycophenolate mofetil in a pediatric Rasmussen syndrome.

Authors :
Orsini A
Costagliola G
Perna D
Esposito MG
Bonfiglio L
Striano P
Peroni D
Consolini R
Bonuccelli A
Source :
Epilepsy & behavior reports [Epilepsy Behav Rep] 2019 Oct 21; Vol. 13, pp. 100334. Date of Electronic Publication: 2019 Oct 21 (Print Publication: 2020).
Publication Year :
2019

Abstract

Rasmussen syndrome (RS) is a chronic encephalopathy with uncertain etiology and immune-mediated pathogenesis. The only definitive treatment is represented by functional hemispherectomy. We describe the case of a 6.5-year-old female patient who developed several episodes of focal, unilateral clonic seizures. Following laboratory and instrumental investigations, the patient was diagnosed as having RS. A treatment with corticosteroids, intravenous immunoglobulin, and the antiseizure medication (carbamazepine and levetiracetam) did not completely control the seizures. Therefore, the patient was treated with mycophenolate mofetil (MMF), showing a good clinical response, with reduction of the seizures, and stability of the radiological findings. This case suggests the potential utility of MMF in the immune approach to RS.<br />Competing Interests: The authors declare no conflict of interest.<br /> (© 2019 The Authors.)

Details

Language :
English
ISSN :
2589-9864
Volume :
13
Database :
MEDLINE
Journal :
Epilepsy & behavior reports
Publication Type :
Academic Journal
Accession number :
32140679
Full Text :
https://doi.org/10.1016/j.ebr.2019.100334